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A series of three dose escalating studies were conducted to investigate the ability of the 17a-hydroxylase/C17,20-lyase inhibitor
abiraterone acetate, to cause maximum suppression of testosterone synthesis when delivered to castrate and noncastrate males with
prostate cancer. Study A was a single dose study in castrate males. Study B was a single dose study in noncastrate males and study C
was a multiple dose study in noncastrate males. The drug was given orally in a once-daily dose and blood samples taken to assess
pharmacokinetic (PK) parameters and hormone levels in all patients. The study drug was well tolerated with some variability in PKs.
Suppression of testosterone levels to o0.14nmoll
 1 was seen in four out of six castrate males treated with a single dose of 500mg.
At 800mg given days 1–12 in noncastrate males, target suppression was achieved in three out of three patients, but a two- to three-
fold increase of Luteinising Hormone (LH) levels in two out of three patients overcame suppression within 3 days. All patients in the
multiple dose study developed an abnormal response to a short Synacthen test by day 11, although baseline cortisol levels remained
normal. This is the first report of the use of a specific 17a-hydroxylase/17,20-lyase inhibitor in humans. Repeated treatment of men
with intact gonadal function with abiraterone acetate at a dose of 800mg can successfully suppress testosterone levels to the castrate
range. However, this level of suppression may not be sustained in all patients due to compensatory hypersecretion of LH. The
enhanced testosterone suppression achieved in castrate men merits further clinical study as a second-line hormonal treatment for
prostate cancer. Adrenocortical suppression may necessitate concomitant administration of replacement glucocorticoid.
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Prostate cancer continues to present an enormous challenge in the
UK, where it is the second most common cause of cancer death in
men, causing over 9000 deaths per year (Cancer Research UK,
2002).
The beneficial effect of androgen ablation on metastatic prostate
cancer was realised in the 1940s, when Huggins and Hodges
observed an antitumour response, as measured by a reduction in
serum acid phosphatase, in patients treated by surgical or medical
castration (Denmeade and Isaacs, 2002). In general, androgen
deprivation will give a response of varying duration in 80–90% of
men with advanced disease (Denis and Murphy, 1993). Although
the multistep pathway of androgen production resulting in
testosterone (Figure 1) is present only in its entirety within the
testes, the adrenal gland is also capable of releasing DHEA and
androstenedione. Enzymes for the subsequent conversion of
DHEA and androstenedione to testosterone are present in a
variety of peripheral tissues as well as the prostate (Griffin and
Wilson, 1998).
Studies have shown that these extratesticular sources of
testosterone represent an important alternative source of androgen
stimulation in a significant proportion of patients with prostate
cancer. As much as 10% of baseline circulating testosterone
remains in castrated men, due to peripheral conversion of adrenal
steroids to testosterone (Hellerstedt and Pienta, 2002). First-line
treatment of prostate cancer by androgen deprivation is generally
achieved by medical or surgical testicular castration. This leaves
the testosterone derived from adrenal sources intact.
It is recognised that the development of androgen-independent
prostate cancer is caused, in part, by changes in androgen receptor
regulation, activation of the androgen receptor being mitogenic in
this malignancy. The sensitivity of the androgen receptor is
increased by the overexpression of two nuclear coactivators:
transcriptional intermediary factor 2 and steroid receptor coacti-
vator 1. Transactivation of the androgen receptor is thus enhanced
at lower concentrations of testosterone (Gregory et al, 2001a,b).
Furthermore, amplification of the number of androgen receptors
can be shown in hormone refractory tumours, when compared
to both benign prostatic hyperplasia and primary prostatic
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lmalignancy, using both reverse transcription PCR and fluorescence
in situ hybridisation (Bubendorf et al, 1999; Linja et al, 2001).
The imidazole derivative ketoconazole and the aromatase
inhibitor aminoglutethimide have been evaluated as possible
agents with which to achieve decreased production of adrenal
steroids. Ketoconazole is relatively unselective, inhibiting both
cholesterol side chain cleavage and 11b-hydroxylation (Loose et al,
1983). A direct antitumour effect of ketoconazole in vitro has also
been demonstrated (Eichenberger and Trachtenberg, 1988). The
action of aminoglutethimide is primarily to block the formation of
pregnenolone from cholesterol but it is also recognised to inhibit
11b-hydroxylase and peripheral aromatase (Schwimmer and
Parker, 1996). In clinical trials, both agents have shown some
activity as second-line agents (measured by clinical benefit as well
as reduction in PSA), supporting the concept of a more selective
inhibitor of the 17a-hydroxylase/C17,20-lyase enzyme (Oh, 2002).
The novel 17a-hydroxylase/C17,20-lyase inhibitor abiraterone
acetate (Figure 2) was developed as a mechanism-based steroidal
inhibitor following observations that nonsteroidal 3-pyridyl esters
had improved selectivity for inhibition (Rowlands et al, 1995).
Abiraterone acetate is the 3-acetate and a prodrug form of CB7598
(17-(3-pyridyl)androsta-5,16-dien-3b-ol, abiraterone), a potent
inhibitor of the enzyme with a Kiapp of 0.5nM (Barrie et al, 1997;
Potter et al, 1995).
Using a rodent model, following intraperitoneal administration,
abiraterone acetate showed rapid deacetylation. Levels of deace-
tylated drug reached 41mM at 6h, with persistence of relatively
high levels of compound (approximately 0.3mM) for at least 24h.
Although this finding may be indicative of depot characteristics of
the mode of administration used, it may also indicate a degree of
enterohepatic recirculation that could prove favourable in the
clinical setting, providing sustained target enzyme inhibition.
In these preclinical studies, there was correlative evidence of
inhibition of 17a hydroxylation as shown, for example, by the
reduced weight of the ventral prostate (Barrie et al, 1994; Dowsett
et al, 1988).
Here, we describe a series of three phase one trials in which
abiraterone acetate was tested in humans for the first time. This is
the first report of the effects of a specific 17a-hydroxylase/C17,20-
lyase inhibitor in humans. The studies were conducted to
determine the dose of abiraterone acetate that will result in
maximum suppression of testosterone and to obtain safety,
pharmacokinetic (PK) and endocrine data, the latter to determine
the specificity of inhibition. All three studies involved patients with
advanced, that is, unresectable, prostate cancer.
METHODS
Patients were recruited to one of the following three studies that
were conducted in sequence. The study protocols were approved
by the Research Ethics Committee of all participating institutions,
and all patients gave written informed consent prior to inclusion.
All three studies were conducted under the auspices of the Cancer
Research UK Phase I/II Committee.
Study A
This was a single dose study in males with castrate levels of
testosterone (testosterone p2nmoll
 1) following orchidectomy or
Gonadotrophin-Releasing Hormone agonist (GnRHa) therapy, to
Cholesterol
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Figure 1 Steroid synthesis pathway. DHEA¼dehydroepiandrosterone; 5ared¼5areductase; DHT¼dihydrotestosterone.
RO
N
Figure 2 Abiraterone structure. R¼H: abiraterone (CB7598); R¼Ac:
abiraterone acetate (CB7630).
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ldetermine the dose of abiraterone acetate that was sufficient to
cause suppression of testosterone synthesis to undetectable levels
(o0.14nmoll
 1). Significant suppression was defined as either
testosterone o0.14nmoll
 1 in individual patients with a pretreat-
ment value of o0.6nmoll
 1 or a X75% reduction in individual
patients with a pretreatment value of X0.6nmoll
 1.
Study B
This was a single dose study in noncastrate males (testosterone
level X9.0nmoll
 1) to determine the dose of abiraterone acetate
that was sufficient to cause suppression of testosterone synthesis to
castrate levels (p2.0nmoll
 1).
Study C
This was a multidose study (Days 1–12) in noncastrate males to
determine the dose of abiraterone acetate that was sufficient to
cause persistent suppression of testosterone synthesis to castrate
levels. If this level of suppression was achieved, then it was planned
to escalate the doses still higher to establish whether further
suppression of testosterone was possible. Complete suppression of
testosterone synthesis should result in testosterone levels
o0.7nmoll
 1, based upon local data, indicating that the mean
value for testosterone in patients on GnRH agonist therapy is in
the region of 0.7nmoll
 1.
In all three studies, the secondary objectives were as follows:
  to determine the safety and tolerability of abiraterone acetate in
the single and multiple dose setting;
  to study the PKs of this compound; and
  to determine any other endocrine effects especially suppression
of cortisol synthesis.
INVESTIGATIONAL AGENT
Abiraterone acetate was provided by Boehringer Ingelheim as a
micronised powder and prepared by the Cancer Research UK
Formulation Unit (Glasgow) as 10, 50, 100 and 200mg dry-filled
capsules. The capsules were stored at room temperature.
PATIENT POPULATION
Patients were required to be at least 18 years of age with a WHO
performance status of p2. No radiotherapy or hormonal therapy
(with the exception of GnRHa in Study A as described above) was
allowed within 6 weeks prior to study, although patients were
allowed to receive concomitant bisphosphonates. Entry was further
restricted to patients with haemoglobin X10.0 gdl
 1, WBC
X4.0 10
9l
 1, platelet count X100 10
9l
 1, alkaline phosphatase
less than twice the upper limit of normal and a urea, creatinine and
bilirubin of not more than 25% above the normal range. Patients
were excluded with coexistent serious nonmalignant disease and
were not allowed to take concomitant steroids. All patients had
stable recurrent malignancy. At the time of participation in these
trials, none of the patients was considered to require any
alternative therapeutic intervention for symptomatic or progres-
sive disease.
DOSAGE AND ADMINISTRATION
Study A
This was a single-centre, open-label, phase one, single-dose study
in which sequential cohorts of three medically or surgically
castrate patients were to receive treatment at five dose levels:
starting at 10mg and increasing to 30, 100, 200 and 500mg. Prior
to study entry all patients must have had an orchidectomy or have
received (and continued to receive) ongoing treatment with a
GnRH agonist for at least 2 months. A confirmatory testosterone
level of between 0.2 and 2.0nmoll
 1 was also required.
Study B
This was a single-centre, open-label, phase one, single-dose study
in which sequential cohorts of three noncastrate patients were to
be treated at four dose levels: 200, 500, 650 and 800mg. The
starting dose of 200mg was chosen when the results of study A
were available. It was envisaged that a dose level would be
expanded to five patients if
  one patient at any dose level experienced XGrade 3 toxicity
  there was a significant suppression of serum cortisol in one
patient as defined as a greater than 50% reduction in levels of
cortisol, or a smaller fall associated with hypotension (systolic
BP less than 90mmHg) or persistent electrolyte disturbance.
  if the target suppression of testosterone was achieved in three
patients at any one dose level.
All patients were required to have a normal testosterone level
prior to study entry (i.e. X9.0nmoll
 1) as well as normal
gonadotrophin levels (Luteinising Hormone (LH) p13IUl
 1).
Study C
This was a three-centre, open-label, phase one, multidose study in
which sequential cohorts of three noncastrate patients were to
receive treatment with abiraterone daily for 12 days. All patients
were required to have a normal testosterone level (X9.0nmoll
 1)
as well as normal gonadotrophin levels (LHp13IUl
 1) prior to
study entry.
The starting dose of 500mg was based upon the data from the
single-dose studies. It was planned that a dose level would be
expanded to six patients if any patient experienced toxicity X
Grade III or if there was a significant suppression of serum cortisol
in one patient (defined as per Study B above). All patients were
followed for 28 days for any sign of toxicity. If any patient
developed symptoms suggestive of progressive disease, confirmed
by a rise in PSA during the study period, they would have been
offered standard treatment with a GnRH agonist.
In all studies, the capsules were administered in one oral dose at
0930 following an overnight fast. Free fluids were permitted and
patients were allowed a light snack 4h after dosing on the day of
PK sampling.
PRETREATMENT ASSESSMENT AND FOLLOW-UP
INVESTIGATIONS
Prior to the first dose of therapy a complete history, physical
examination and assessment of performance status was performed
on all patients. Full-blood count, electrolytes and creatinine, liver
function, urinanalysis, electrocardiograph and chest X-ray were
obtained from all patients. The ECG was repeated 6h after dosing.
On the day of therapy heart rate, blood pressure and temperature
were recorded every 4h and then daily at the time of blood sampling.
Thereafter, full-blood count, electrolytes, creatinine and liver
function were re-evaluated on Days 2 and 7. Toxicity was recorded
using the NCI-CTG Expanded Common Toxicity Criteria V1.
ENDOCRINE ASSESSMENT
Study A and B
Serum samples for endocrine analysis were obtained at 0, 2, 4, 8
and 24h on a single day in the week prior to treatment
Abiraterone acetate – hormonal and PK study
A O’Donnell et al
2319
British Journal of Cancer (2004) 90(12), 2317–2325 & 2004 Cancer Research UK
C
l
i
n
i
c
a
lcommencement and then on Days 1, 2, 3, 4 and 7. As the duration
of testosterone suppression was longer than originally anticipated,
additional samples were added on Days 10, 14 and 21. The serum
samples were analysed for testosterone, cortisol, 17 a-hydroxy-
progesterone (17HP), androstenedione, LH and follicle-stimulating
hormone (FSH) using commercially available kits. However, the
DPC Coat-a-count kit for testosterone was sensitised using a larger
volume of sample/standard and extension of the standard curve.
Prior to study initiation, this was demonstrated to have no
significant effect on the values of testosterone measured but to
provide sensitivity to a level of 0.05nmoll
 1. All endocrine
analyses were conducted by radioimmunoassay except for LH
and FSH, which were by enzyme immunoassay.
Study C
The schedule sampling differed slightly with samples removed at
0930 and 1730 on the day of treatment and thereafter in the
morning on Days 2, 3, 4, 7, 8, 9, 10, 11, 14, 21 and 28. In Study C, a
short Synacthen test was also performed prior to therapy and again
around Day 11.
PKS – ANALYTIC METHOD, ASSAYS AND SAMPLING
Sample extracts were analysed by a fully validated liquid
chromatography mass spectrometry method. The instrument
consisted of Wisp Model 717 autosampler including a Model
600MS system controller with a quaternary U6K LC pump. A
Finnigan MAT TSQ 700 triple quadrupole mass spectrometer was
used as the detection system, together with Finnigan MAT ICIS
and ICL software for data capture and processing (ThermoQuest
Ltd, San Jose, CA, USA). The separation of analytes was performed
on a Supelcosil LC-ABZ (5mm, 250 4.6mm) analytical column
protected by a guard column (Supelco, Bellefonte, PA, USA). The
mobile phase consisted of 570ml of 20mM ammonium acetate
solution, 100ml tetrahydrofuran and 1330ml acetonitrile and was
delivered at a flow rate of 1mlmin
 1 throughout the system.
Column eluant was subjected to electrospray ionisation and
monitored by selected ion monitoring (SIM) of protonated
pseudo-molecular ions of authentic standards of abiraterone
acetate and abiraterone, and GP488 (an analogue of abiraterone
used as internal standard). For SIM, the scan width was 0.25 and
the total scan time was 2.99s. Also, heated capillary
temperature¼2501C, spray voltage¼4.5kV, collision off-
set¼ 49.9V and electron multiplier voltage¼1200eV.
Samples were extracted as follows: 50ml of acetonitrile and 40ml
of 50mM GP488 internal standard were added to 500ml of patient
plasma. After the addition of 3ml hexane:butanol (98:2, v/v) and
2min vortexing, 2ml aliquots of the organic layer were transferred
for drying in vacuo for 2h. The dried residue was reconstituted by
vortexing in 150ml of acetonitrile and transferred into autosampler
vials. Aliquots (100ml) of these samples were injected onto the LC
column. Calibration curves were obtained by plotting peak area
ratios for abiraterone acetates or abiraterone to internal standard
vs the nominal analyte concentrations using linear regression by
Microsoft Excel version 5.0 (Microsoft, Redmond, WA, USA).
Calibrations curves were produced at the levels of 500 and 1000nM
for abiraterone acetate and 6.25, 12.5, 25, 50, 100 and 500nM for
abiraterone. Quality controls were included at the level of 8, 40 and
400nM for abiraterone and 500nM for abiraterone acetate.
A comprehensive PK profile (Cmax, Tmax, T1/2a T1/2 and Kabs) was
determined for each patient. Pharmacokinetic parameters were
evaluated using WinNonLin Softwares and were conducted at
The Institute of Cancer Research (Sutton).
Blood was sampled for analysis of abiraterone concentration
prior to drug administration and at the following times on Day 1:
30min, 1, 2, 4, 6, 8 and 12h. In the multidose study, samples were
also drawn prior to treatment on Days 2, 3, 4, 7, 8, 9, 10, 11 and 14
with additional samples on Days 21 and 28. Samples (7ml) were
collected into vacutainer tubes (BD, Rutherford, NJ, USA)
containing EDTA and immediately centrifuged to separate the
plasma. At least 2ml of plasma was transferred into polypropylene
tubes (NUNC) and frozen at –201 until analysis.
RESULTS
Study A
A total of 16 male patients with histologically confirmed advanced
adenocarcinoma of the prostate were enrolled. All patients had
received previous antiandrogen therapy (flutamide or cyproterone
acetate) and at time of enrolment in this study all were receiving
treatment with a GnRH agonist; leuprorelin or goserelin. All
patients were evaluable for safety, PK and endocrine assessments.
The group had a median age of 73.5 years (Range 63–77 years) and
all were performance status 0, 1.
Endocrine Sequential cohorts of three patients were treated at 10,
30 and 100mg. At these doses no consistent effect on testosterone
was observed and the plasma concentrations of abiraterone were
below the level of detection. Patient 4 (30mg dose level) was
observed to have noncastrate levels of testosterone during the
study period despite a satisfactory screening testosterone level of
1.3nmoll
 1. On further questioning, it was discovered that there
had been suboptimal compliance with goserelin therapy and he
was deemed ineligible.
A dose escalation to 500mg was considered necessary as a result
of the absence of a pharmacodynamic effect at doses up to 100mg
after one patient had already consented to and had received therapy
at 200mg. A 75% reduction in testosterone was observed in this
patient within the first 24h after treatment with abiraterone. In all
three patients treated at 500mg, a reduction in testosterone to the
target level was seen (o0.14nmoll
 1 or X75% reduction in
baseline level testosterone X0.6mmoll
 1). The duration of the
suppression was variable. In two of the three patients, suppression
was sustained from Days 2 to 5 post-therapy. Three additional
patients then received treatment at 500mg. Target testosterone
suppression was seen in one of these patients. The same level of
suppression was not observed in the remaining two apparently due
to incorrect prior dosing with goserelin and therefore escape of
testosterone levels to noncastrate levels during the study period.
These results are illustrated in Figure 3. At the 500mg dose level, a
reduction in mean androstenedione levels was parallel to the
reduction in mean testosterone levels, occurring around Day 2. It
was notable that there was no corresponding reduction in the levels
of 17-hydroxyprogesterone. A reduction in serum cortisol levels
was seen in one patient treated at 500mg, baseline 409nmoll
 1,
falling to 81nmoll
 1 Day 1. However, as this reduction was
apparent at the first time point on Day 1 it was felt to be
inconsistent with suppression due to abiraterone. On questioning
this patient denied the concomitant use of glucocorticoids.
Study B
Four male patients with histologically confirmed advanced
adenocarcinoma of prostate were recruited. All patients had
received prior antiandrogen therapy and previous therapy with a
GnRH agonist but at the time of study entry had a serum
testosterone of 49nmoll
 1. All patients were evaluable for safety,
PK and endocrine assessments. The group had a median age of
71.5 years (range 60–77 years), and had performance status 0.
Endocrine The first patient received treatment with abiraterone
at 200mg. No testosterone suppression was observed and three
further patients were then treated at 500mg. In all three patients a
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lreduction in testosterone level of more than 50% from baseline was
seen. The testosterone nadir was observed on the second day after
therapy with recovery to pretreatment levels 6–9 days later. A
corresponding rise in LH levels was seen (47–75%) maximal on
Day 3 with recovery to pretreatment levels by Day 10 (Figure 4).
No change in cortisol level was seen.
Study C
Six male patients with histologically confirmed advanced adeno-
carcinoma of the prostate were accrued. Five of the six had
received prior antiandrogen therapy and the same five of six had
received and completed prior therapy with a GnRH agonist. At the
time of study entry, all patients had a testosterone level of
49nmoll
 1. The group had a median age of 68.5 years (Range
62–80 years) and had performance status 0 or 1.
Endocrine An initial cohort of three patients received treatment
at 500mg. Although a reduction in testosterone level to
p2.0nmoll
 1 was seen in all three patients, this did not reach
the target level of p0.7nmoll
 1. The pattern of suppression was
variable with maximal suppression occurring Days 1–3 and
substantial suppression sustained for up to 9 days (Figure 5).
While serum cortisol levels remained within normal limits all three
patients had an abnormal response to Synacthen by Day 11. The
mean change in cortisol in response to Synacthen was
294.3nmoll
 1 (i.e. þ77%) at baseline in the patients treated with
500mg, falling to only 42nmoll
 1 (þ10%) by Day 11. A further
cohort of three patients was then treated at 800mg to investigate
whether target testosterone suppression (p0.7nmoll
 1) could be
reached. In the first patient, target suppression was obtained on
Day 1, sustained for 3 days and then reversed in association with
rising LH (three-fold increase) from Day 3. Despite this
testosterone levels remained p2.0nmoll
 1 for the duration of
treatment. In the second, target suppression was reached on Day 4,
testosterone rose to 0.77nmoll
 1 on Day 7 but otherwise remained
below the target level for the duration of treatment. In the final
patient, testosterone fell to 1.7nmoll
 1 by Day 2 but then rose
again to 42.0nmoll
 1 from Day 4. A concomitant two-fold rise in
LH was seen from Day 3 in this patient.
The first and third patients treated at 500mg had higher LH
levels at baseline than all patients treated at 800mg. This may have
contributed to the difficulty in achieving suppression of testoster-
one at the lower dose level. As in those treated at 500mg, the
cortisol response to the short Synacthen test in all three patients
treated at 800mg was abnormal on Day 11. The mean change in
cortisol levels in response to Synacthen was 385nmoll
 1 (120%) at
baseline in this cohort of patients, falling to an increment of
65.3nmoll
 1 (23%) by Day 11. Serum cortisol levels were
themselves reduced by the evening of Day 1 in three patients but
all other assessments remained within normal limits. Evening
cortisol falling by 60, 71 and 69%, respectively, from baseline
evening cortisol in these three patients.
PHARMACOKINETICS
The PK parameters all show considerable variability between
patients and are presented in Table 1. The plasma concentration of
abiraterone at the first three dose levels in study A was below the
level of detection of the assay precluding analysis of the PK
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Figure 3 Selected mean hormone levels in castrate men receiving a
single dose of abiraterone acetate.
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Figure 4 Serial hormone levels in noncastrate patients treated with a
single oral dose of abiraterone acetate.
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lbehaviour. At 100mg, concentrations were low and the terminal
half-life was unable to be determined confidently. Detectable levels
were obtained at all doses greater than or equal to 200mg. Data are
not available for one patient treated at 500mg due to an assay that
failed quality control.
The mean Tmax was 2.70h (7s.d. 2.71) with a mean elimination
half-life of 27.6h (7s.d. 20.17). A range of up to 10-fold in AUC
was seen for a given dose.
Within the patient groups studied, we were unable to identify
any distinguishing characteristics to explain this further. The level
of interpatient variability made analysis of dose-dependent PK
relationships difficult. Combining the data from all three studies,
while the mean AUC at each dose level increased with dose, it
appeared that the association between AUC and dose is nonlinear
(R
2¼0.34). There was no evidence of saturation of drug
absorption at the dose levels studied (Table 2 and Figure 6).
OVERALL TOXICITY
In all three trials, abiraterone acetate was very well tolerated and
no serious adverse events attributable to treatment were recorded.
No haematologic or biochemical effects were observed at any dose
level or schedule evaluated. No alteration in resting heart rate or
blood pressure was seen. Systemic effects attributable to abirater-
one were uncommon. Headache, hot flushes, a mild increase in
abdominal and testicular pain, and a transient depression in mood
(all grade II) were reported by individual patients but no relation
to dose or schedule was apparent. There were no grade three or
four toxic events.
DISCUSSION
These are the first data to describe the systematic assessment of the
endocrine effects of a specific 17a-hydroxylase/C17,20-lyase in-
hibitor in humans. The endocrine results that will determine the
further development of abiraterone acetate are likely to be
qualitatively representative of other drugs of this class.
The single dose study in castrate patients demonstrated that
treatment with abiraterone acetate results in sustained suppression
of the testosterone/androstenedione axis. The protracted duration
of this suppression is possibly due to the irreversible nature of the
drug action. In turn, therefore, one may predict that it may be
possible to increase the effect with continuous dosing. This single
dose study showed no effect on 17a-OH-progesterone production.
This indicates that any inhibition of 17a-hydroxylation that may
occur as a result of treatment with abiraterone acetate is over-
ridden by compensatory mechanisms related to cortisol feedback.
Despite 17a-hydroxylase and C17,20-lyase activities being contained
in a single enzyme the compensated effect on 17a-hydroxylase
activity clearly did not prevent an inhibition of C17,20-lyase (as
evidenced by androgen suppression). Supportive evidence for this
is provided by the observation that there was no significant effect
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Figure 5 Serial hormone levels in noncastrate patients treated with multiple oral doses of abiraterone acetate.
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lon cortisol levels in these patients. Since this study was conducted
in castrate patients, the data assess adrenal function as opposed to
mostly testicular function.
In the single dose study of noncastrate patients, there appeared
to be a steep dose–response relationship. In the patients treated at
200mg, no effect was observed in testosterone levels and this was
not because of compensation by LH (as LH levels did not alter). At
500mg treated patients showed persistent reductions in testoster-
one levels. In each case the level of testosterone on Day 3 was less
than 50% that of baseline, despite increased LH levels in these
patients. Again there was no indication in this component study of
the series that there was any effect on baseline cortisol levels
despite what would appears to be a persistent block in C17,20-lyase
activity.
From the repeat dose studies it can be seen that a dose of at least
800mg is required to maintain testosterone suppression to target
levels. In two patients treated at this dose level there was a marked
rise in LH, which appeared to restrict the duration of testosterone
suppression. However, in a further patient there was no
compensatory LH response and testosterone levels remained very
low. At 800mg there was no effect on FSH levels apparent.
Although baseline cortisol levels remained normal, all patients
treated at 500 and 800mg in the multiple dose study developed an
abnormal response to a short Synacthen test by Day 11. Some
impact on adrenal reserve was predictable from the steroid
synthesis pathway.
In the clinical use of both aminoglutethimide and ketoconazole,
it is common practice to administer supplementary hydrocortisone
and this may prove necessary with 17a-hydroxylase and C17,20-
lyase inhibitors such as abiraterone acetate. However, the omission
of glucocorticoid replacement when treating with aminoglutethi-
mide and ketoconazole has been shown to be safe and effective
(Eichenberger and Trachtenberg, 1988; Dowsett et al, 1988;
Harnett et al, 1987; Rostom et al, 1982). In the light of this
clinical evidence, further studies with abiraterone acetate will be
required to ascertain if concomitant therapy with glucocorticoid is
required on a continuous basis, at times of physiological stress, if
patients become symptomatic or indeed at all.
Table 1 Summary of pharmacokinetic data for abiraterone acetate when given orally in single and multiple dose studies
Patient Dose (mgm
 2) AUC (lMh
 1) Cmax (lM) Tmax (h) T1/2a (h) T1/2b (h) Kabs (h)
11 0 N D N D N D N D N D N D
2 10 ND 0.001 2 ND ND ND
3 10 ND 0.018 11 ND ND ND
43 0 N D N D N D N D N D N D
5 30 ND 0.004 4 ND ND ND
6 30 ND 0.006 1 ND ND ND
7 100 0.15 0.012 13 6.5 ND 6.5
8 100 0.09 0.011 0.16 0.97 26.5 0.03
9 100 0.12 0.019 3.7 2.0 28 1.8
10 200 0.39 0.061 2.8 1.59 25.8 3.87
11 500 0.25 0.063 0.8 0.28 29 0.01
12 500 1.68 0.139 3.7 1.83 21 1.8
13 500 0.73 0.06 3.6 1.73 74 1.71
14 500 0.67 0.066 4 1.43 18 1.41
15 500 0.42 0.077 2 0.29 13.4 1.00
16 500 1.38 0.167 2.7 0.05 13.3 1.15
17 200 0.23 0.037 0.69 1.49 28 0.03
18 500 1.23 0.054 1.7 0.19 14.6 0.3
19 500 1.101 0.183 1.51 0.71 14 0.7
20 500 2.08 0.30 1.41 1.59 24 0.12
21 500 3.54 0.62 1.70 1.07 23.2 0.82
22 500 0.34 0.07 2.30 0.79 12.0 0.80
23 500 NE NE NE NE NE NE
24 800 11.66 1.19 3.02 1.32 87 1.34
25 800 2.32 0.43 1.20 0.45 19.9 0.45
26 800 2.84 0.18 3.10 1.73 26.2 1.82
Details of subjects: PT 1–16: single dose study in castrate males; PT 17–20: single dose in noncastrate males; PT 21–26: multidose study in noncastrate males. NE¼not
evaluated due to problems with the assay; ND¼not detectable, plasma concentrations too allow to permit estimation of the pharmacokinetic behaviour of the drug;
AUC¼area under the concentration time curve; Cmax¼maximum concentration, Tmax¼time to maximum concentration; T1/2a¼initial half-life; T1/2b¼terminal half-life;
Kabs¼absorption rate constant.
Table 2 Summary of abiraterone clearance across all three studies
Dose (mg) Mean AUC (lMh
 1)
200 0.31
500 1.22
800 5.60
AUC¼area under the dose/concentration curve.
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Figure 6 Relationship between dose and AUC for abiraterone acetate
given orally for all three studies. R
2¼linear regression coefficient; AUC:
area under the dose/concentration curve.
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lThe level of interpatient variability made analysis of dose-
dependent PK relationships in these studies difficult. The majority
of patients reached maximum drug concentration within 4h of
administration with an elimination half-life of approximately 29h.
However, there was up to a 10-fold variation in AUC for a given
dose. This is largely accounted for by two distinct groups of
outliers. Firstly, a small number of patients who absorbed the
compound more quickly, reaching maximum concentration within
an hour. Secondly, a group of patients in whom the elimination
half-life was extremely prolonged and exceeded 70h. Several
factors may theoretically contribute to such a variation particularly
with an oral compound. Patterns of absorption may be influenced
by the presence of residual food in the stomach despite an
overnight fast, by intrinsic interindividual differences in upper
gastrointestinal pH or by interaction with other concomitant
medication exerting an influence on gastric pH. Furthermore,
these studies were performed using capsules containing simply
loose-filled, micronised powder and we cannot exclude the
possibility that this formulation might accentuate such effects.
Greater interpatient consistency might be achieved with a capsule
containing a more homogeneous formulation, as a melt or with
excipients, to aid reproducible dissolution. Interindividual differ-
ences in body fat percentages may lead to differences in the
available volume of distribution. Lastly, there may be significant
interpatient differences in the rate of drug metabolism due to the
effect of concomitant medication on enzyme function or
pharmacogenomic characteristics.
The association between AUC and dose appeared nonlinear
when results from all three studies were combined. As there were
only three patients at the 800mg level, each contributed
proportionately more to the overall result. The particularly high
AUC, high Cmax and protracted b-half-life of abiraterone in patient
24 treated at 800mg were noted; this patient may represent a true
outlier to the overall relationship between AUC and dose,
but additional PK information in patients receiving 800mg would
be helpful.
The degree of PK interpatient variability with abiraterone
acetate is at the high end of the spectrum seen with oral anticancer
compounds (DeMario and Ratain, 1998). However, as abiraterone
is well tolerated and there is an appropriate and minimally invasive
measure of efficacy against which to titrate the dose, this degree of
variability is tolerable and should not limit clinical utility.
In addition to ketoconazole, aminoglutethimide and abirater-
one, other compounds designed to inhibit general androgen
production have been developed and show promise. Brodie and
colleagues have described a series of novel steroidal inhibitors of
androgen synthesis. The most potent of these L39, a D4-3-one-
androstane derivative, is able to lower androgen levels effectively
in animal models and inhibit tumour growth of androgen-
dependent cancer cells in both in vitro and in vivo studies. It
appears that this effect is not simply the result of C17,20-lyase
and/or 5a reductase activity but is also mediated through a
negative interaction directly with the androgen receptor (Long
et al, 2001).
These studies demonstrate for the first time the potential utility
of specific inhibition of 17a-hydroxylase/C17,20-lyase in causing
reductions in testosterone levels in both castrate and noncastrate
males with prostate cancer. The data indicate that reliably
maintaining castrate testosterone levels in intact males in the face
of increased levels of LH may require higher doses of abiraterone
acetate. The present data, however, do support the potential
utility of this drug in the second-line treatment of patients who
have become refractory to gonadotrophin-releasing hormone
agonists. In recent years, it has become routine to continue
treatment with these agents in spite of disease progression, since
without this, androgen stimulation may return. This being
the case, a sustained further reduction in testosterone should be
achievable with abiraterone acetate since the compensatory
LH drive would be suppressed by the GnRH agonist. This
hypothesis needs to be tested in a chronic dosing Phase I/II
study in GnRH-resistant prostate cancer in the presence of
continued GnRH dosing.
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